Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree.
Think we have good chance to see nice development here for the rest of the year and later...
Good time to you...
9th Annual CAR-TCR Summit
Sep 17 - Sep 20, 2024
The Immatics team will attend the CAR-TCR Summit.
For more information, visit the summit website by clicking here.
Location
Boston, Massachusetts, USA
Yes it was...
There will be more news soon.
The first premarket was 11,40...So it was a great day...
I agree...
Perhaps we will close green....
Ah okay...
In the end this could be an advantage to have all rights back IMO...
Not really...
I did some DD on BMS. At the moment they seem to have more problems with their own business and their numbers. I think the reason for this decission is more likely to find by BMS themselves than by Immatics.
My second thought was: If BMS is out Immatics could be much more attractive for M & A...
Not really...
I did some DD on BMS. At the moment they seem to have more problems with their own business and their numbers. I think the reason for this decission is more likely to find by BMS themselves than by Immatics.
My second thought was: If BMS is out Immatics could be much more attractive for M & A...
Interesting thoughts! But could be!
Let's do so!
Looking for a nice week/weeks here...
Perhaps interesting to read for you with google translate....
https://www.boerse-online.de/nachrichten/aktien/geheimtipp-diese-voellig-unbekannte-biotech-aktie-aus-deutschland-hat-niemand-auf-dem-schirm-20352622.html
Thank you too for sharing your information!
Yes, I'm from Germany...
That could give a great push in PPS...Not Long ago they finished a big production facility in Germany...together that all makes sence
I agree. I would say 80 %. But this would mean a fantastic result!
Volume rises....
Yes,I mean too with RMAT...
It's very interesting they announce that something will be announced. This only makes sense If something positive will be presented IMO...
This here can become very interesting very soon...Good data can also wake up "Big Pharma" very soon...I believe good times already in 2024...
Very interesting...even I don't understand everything...but the second half of the year seems to become promising...
Agree, else they would not file a news for this...
That all sounds good!
I hope tomorrow we will see a move like Friday...
Interesting! Thank u!
I'm very optimistic IMTX is on a good path!
I wonder a little bit about the course. I would say we should be at 20 th right now.
Perhaps some shortseller try to keep it a little bit down...But this will change in the near future - IMO.
If IMA203 gets admission by FDA WE should very quickly see 30-50...
Next takeover in the biotech sector...
https://ir.genmab.com/news-releases/news-release-details/genmab-broaden-and-strengthen-oncology-portfolio-acquisition
Thank u! Very interesting. I would like to see some higher levels in the PPS before something like M&A....
But perhaps interesting times coming...
Chart looking much better now. IMO good chance to leave these levels now and climb to 20th...
New data should come soon:
New Clinical Data From:
IRCCS Bambino Gesu Children’s Hospital, Immatics, Caribou Biosciences, Carisma Therapeutics, and Kyverna Therapeutics
https://cartcr-europe.com/
February 27-29, 2024
Novartis wants to buy Morphosys...
Interesting is - Immatics and Morphosys and Novartis seem to have connections, too.
Perhaps it's only the beginning of a bigger consolidation in the sector.
https://www.labiotech.eu/trends-news/leading-german-biotechs-morphosys-and-immatics-partner-to-pump-up-their-immuno-oncology-therapies/
Sectors
Drug Development
More
Podcast
Reports
Home News and Trends
Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies
By Philip Hemme
2 mins
August 25, 2015
Updated
:
August 4, 2021
Two German biotechs with highly successful platforms join forces to fight cancer. MorphoSys and Immatics Biotechnologies want to generate novel antibody-based therapeutics against multiple cancer antigens.
They are two of the thriving forces in the German biotech scene. Munich’s MorphoSys claims having developed the most successful antibody library technology in the pharma industry, currently has 100 distinct drugs in research and development and is worth €1.67Bn. Tübingen-based Immatics owns the leading target discovery platform in cancer immunotherapy and raised over €120M. And now they want to team up. What a match!
Here’s how they want to tackle cancer: Tumor cells contain specific peptides that are not present in healthy cells. These are presented on the surface through specialized receptors, so-called major histocompatibility complex (MHC) receptors. The collaboration between Immatics and MorphoSys aims to discover antibodies against these MHC-bound peptide targets in order to kill the tumor cells.
Within the collaboration, MorphoSys gets several tumor-associated peptides that were discovered using Immatics’ platform. These are present in a number of solid and hematological cancers and can be used as antibody targets.
In return, Immatics will be provided with some of MorphoSys’ antibodies against a number of its discovered peptides. The companies will pay each other undisclosed milestones as well as royalties on marketed products.
The partnering is especially valuable for MorphoSys. It had to sustain a major drop of its stock after Celgene had abandoned the company. Since then, both collaborations with Novartis and Heptares Therapeutics advanced. With all these good news, MorphoSys stock slowly recovers.
The merging could pave the way for a leading immuno-oncology player, from which the whole biotech ecosystem could profit.
Bonus, we interviewed the CEO of Immatics Paul Higham during our South German Tour. Here’s the video:
Please accept cookies to access this content
Immatics – Paul Higham, CEO from LabiotechTour on Vimeo.
Interesting!
Think ist's important now to leave the 52 week range and to climb about 13.14....after that it could quickly go to 15 and more...
Thanks! Everything looking promising here. Hope some big Investors will soon come in...
Interesting find! It seem's to me something will happen here in the near future...
Nice volume again!
Immatics Announces Third Quarter 2023 Financial Results and Business Update...
8.30 am conference call....
Interim clinical data out...
Thank u! Seems to have the knowledge in the sector...
Hope to see another nice day with buying pressure...
I agree. Within the next days/weeks we should hear something.
That would be great. In that case we would quickly climb above 50 and more...
Nice to see.Selling pressure seems to bei over....
This prospectus relates to the offer and sale from time to time by Bristol-Myers Squibb Company (the “selling securityholder”) of up to 2,419,818 of our ordinary shares, €0.01 nominal value per share. This prospectus also covers any additional securities that may become issuable by reason of share splits, share dividends or other similar transactions...
I think this is the reason....I believe they don't like the deal with Moderna and sell shares...
I can't understand the PPS. The news was huge, I agree.
I think we have to be patient. If they go their way we'll see totally different courses here. In a view years I would not bet against a range of 50 to 100 dollars here....
14,46 a share! Very good sign in my opinion!
Chart looking very promising now...hope we'll see new alltimehigh soon! But I believe...Biotech is getting popular at the moment - could give us some support too...
Looks interesting...Something coming up!
Nice volume today... something coming up?....
Good sign! Only question of time this will run...